Evaluating and managing cardiovascular disease risk factors in HIV-infected patients

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• Cardiovascular disease (CVD) risk factors in HIV-infected patients largely mirror those in the general population.
• Certain antiretroviral drugs may slightly increase short-term CVD risk, with potential for greater long-term impact.

Purpose of the Study:

• To outline strategies for managing cardiovascular disease risk in patients with HIV infection.
• To emphasize the importance of controlling HIV and metabolic abnormalities concurrently.

Main Methods:

• Review of current understanding of CVD risk factors in HIV.
• Discussion of the role of antiretroviral therapy and lipid-lowering agents.
• Focus on statin therapy for dyslipidemia management in this population.

Main Results:

• Primary CVD risk factors in HIV patients are similar to the general population.
• Absolute CVD risk from antiretroviral drugs is most critical for high-risk individuals.
• Lipid-lowering therapy with statins is highly effective for reducing CVD risk.

Conclusions:

• Effective CVD risk management in HIV patients requires integrated HIV control and metabolic abnormality treatment.
• Targeting low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with statins is key for most patients with dyslipidemia.
• A comprehensive approach is essential for mitigating CVD risk in the context of HIV infection.